MiR-34a inhibits migration and invasion by regulating the SIRT1/p53 pathway in human SW480 cells

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3301-3307

  Lai, Mingguang ^a   Du, Gang ^b   Shi, Ruiyue ^a   Yao, Jun ^a   Yang, Genhua ^a   Wei, Yue ^a   Zhang, Dingguo ^a   Xu, Zhenglei ^a   Zhang, Ru ^a   Li, Yingxue ^b   Li, Zicheng ^a   Wang, Lisheng ^a  

^a SHENZHEN PEOPLE'S HOSPITAL   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

MicroRNA 34a; P53; SIRT1; SW480 cells

Indexed keywords

FLUOROURACIL; MICRORNA 34A; PROTEIN P21; PROTEIN P53; SIRTUIN 1; MICRORNA; MIRN34 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; WESTERN BLOTTING; CELL CYCLE; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922287246     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3182     Document Type: Article

References (40)

1. Stillwell AP, Buettner PG, Siu SK, Stitz RW, Stevenson AR and Ho YH: Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. Dis Colon Rectum 54: 535-544, 2011.
2. Cozzolino AM, Pedace L, Castori M, et al: Analysis of the miR-34a locus in 62 patients with familial cutaneous melanoma negative for CDKN2A/CDK4 screening. Fam Cancer 11: 201-208, 2012.
3. Nalls D, Tang SN, Rodova M, Srivastava RK and Shankar S: Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6: e24099, 2011.
4. Fujita Y, Kojima K, Hamada N, et al: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119, 2008.
5. Winton DJ: miR-34a sets the 'sweet spot' for notch in colorectal cancer stem cells. Cell Stem Cell 12: 499-501, 2013.
6. Gallardo E, Navarro A and Vinolas N, et al: miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909, 2009.
7. Cole KA, Attiyeh EF, Mosse YP, et al: A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6: 735-742, 2008.
8. Dorn GN II: miR-34a and the cardiomyopathy of senescence: SALT PNUTS, SALT PNUTS! Cell Metab 17: 629-630, 2013.
9. Ito T, Yagi S and Yamakuchi M: MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 398: 735-740, 2010.
10. Ghawanmeh T, Thunberg U, Castro J, Murray F and Laytragoon-Lewin N: miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology 81: 330-335, 2011.
11. Kojima K, Fujita Y, Nozawa Y, Deguchi T and Ito M: MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70: 1501-1512, 2010.
12. Guarente L: Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N Engl J Med 364: 2235-2244, 2011.
13. Li X and Kazgan N: Mammalian sirtuins and energy metabolism. Int J Biol Sci 7: 575-587, 2011.
14. Li YG, Zhu W, Tao JP, et al: Resveratrol protects cardiomyocytes from oxidative stress through SIRT1 and mitochondrial biogenesis signaling pathways. Biochem Biophys Res Commun 438: 270-276, 2013.
15. Cui Y, Wang H, Chen H, et al: Genetic analysis of the SIRT1 gene promoter in myocardial infarction. Biochem Biophys Res Commun 426: 232-236, 2012.
16. Csiszar A, Labinskyy N, Jimenez R, et al: Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev 130: 518-527, 2009.
17. Olivier M, Petitjean A, Marcel V, et al: Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16: 1-12, 2009.
18. Lefort K, Brooks Y, Ostano P, et al: A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J 32: 2248-2263, 2013.
19. Wang B, Li D and Kovalchuk O: p53 Ser15 phosphorylation and histone modifications contribute to IR-induced miR-34a transcription in mammary epithelial cells. Cell Cycle 12: 2073-2083, 2013.
20. Chen X, Yan J and Chen T: Expression level of miR-34a rather than P53 gene status correlates with mutability in related human lymphoblast cell lines. Mol Carcinog 51: 674-677, 2012.
21. Yamakuchi M and Lowenstein CJ: MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8: 712-715, 2009.
22. Castro RE, Ferreira DM, Afonso MB, et al: miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58: 119-125, 2013.
23. Yamakuchi M, Ferlito M and Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426, 2008.
24. Kouchi Z, Fujiwara Y, Yamaguchi H, Nakamura Y and Fukami K: Phosphatidylinositol 5-phosphate 4-kinase type II beta is required for vitamin D receptor-dependent E-cadherin expression in SW480 cells. Biochem Biophys Res Commun 408: 523-529, 2011.
25. Gregory RI, Chendrimada TP and Shiekhattar R: MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol Biol 342: 33-47, 2006.
26. Krutovskikh VA and Herceg Z: Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. Bioessays 32: 894-904, 2010.
27. Wei Y, Nazari-Jahantigh M, Neth P, Weber C and Schober A: MicroRNA-126,-145, and-155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 33: 449-454, 2013.
28. Krichevsky AM and Gabriely G: miR-21: a small multi-faceted RNA. J Cell Mol Med 13: 39-53, 2009.
29. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
30. Dufour A, Palermo G and Zellmeier E, et al: Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood 121: 3650-3657, 2013.
31. Duan W, Xu Y, Dong Y, Cao L, Tong J and Zhou X: Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res 54: 611-619, 2013.
32. Feinberg-Gorenshtein G, Avigad S, Jeison M, et al: Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site. Genes Chromosomes Cancer 48: 539-543, 2009.
33. Liu C, Kelnar K, Liu B, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215, 2011.
34. Pritchard DM, Watson AJ, Potten CS, Jackman AL and Hickman JA: Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 94: 1795-1799, 1997.
35. Roos WP and Kaina B: DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 332: 237-248, 2013.
36. Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13: 921-926, 2006.
37. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T and Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197-204, 2011.
38. Audrito V, Vaisitti T, Rossi D, et al: Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 71: 4473-4483, 2011.
39. Tan J, Fan L, Mao JJ, et al: Restoration of miR-34a in p53 deficient cells unexpectedly promotes the cell survival by increasing NFκB activity. J Cell Biochem 113: 2903-2908, 2012.
40. Olmos Y, Sanchez-Gomez FJ, Wild B, et al: SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. Antioxid Redox Signal 19: 1507-1521, 2013.